Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes
BJU International · 2025
DOI: 10.1111/bju.16556 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Reuben Ben-David und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Cystectomy, Urinary Bladder Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess recurrence‐free survival (RFS) in patients with undetectable tumour‐informed circulating tumour DNA (ctDNA) before radical cystectomy (RC) and evaluate if those who converted from detectable to undetectable ctDNA status after RC have similar RFS outcomes as those with persistently undetectable ctDNA status. Patients and Methods Patients who underwent RC had prospectively and longitudinally collected tumour‐informed ctDNA analyses during 2021–2023. ctDNA status was informed from the pre‐RC specimen. The minimal residual disease (MRD) window was defined as the initial 90 days after RC. RFS was evaluated using the Kaplan–Meier method. Cox regression analysis was performed to find predictors of disease recurrence.
Results
The cohort included 135 patients with 647 ctDNA analyses. The median (interquartile range [IQR]) age was 71 (63–77) years. Over a median (IQR) follow‐up of 11 (7–18) months, 41 patients (30%) had a recurrence. Pre‐RC undetectable ctDNA status was found in 54 patients (40%). The RFS rates at 6, 12, and 21 months were 98%, 93%, and 82%, respectively. Of 77 patients with undetectable ctDNA status at the MRD window available for conversion dynamics analysis, 43 had persistently undetectable ctDNA status (both at pre‐RC and MRD window) and 31 converted from pre‐RC detectable to MRD undetectable status (conversion group). The persistently undetectable group had significantly better RFS than the conversion group (log‐rank, P < 0.001), with 12‐month RFS rates of 97% vs 51%, and 18‐month RFS rates of 88% vs 51%, respectively. On Cox multivariate analysis, only the conversion group status predicted disease recurrence.
Conclusions
Patients with undetectable pre‐RC ctDNA status have a favourable prognosis and may be candidates for treatment de‐escalation. Those with persistently undetectable ctDNA had superior RFS compared to the conversion group. Pre‐RC ctDNA status should be incorporated into trials examining ctDNA use in clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Reuben Ben-David, Sarah Lidagoster, Jack Geduldig, Kaushik P Kolanukuduru, Yuval Elkun, Neeraja Tillu, Asher Mandel, Mohammed Almoflihi, Basil Kaufmann, Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P Sfakianos
Zitieren
APA
Ben-David, R., Lidagoster, S., Geduldig, J., Kolanukuduru, K. P., Elkun, Y., Tillu, N., Mandel, A., Almoflihi, M., Kaufmann, B., Attalla, K., Mehrazin, R., Wiklund, P., & Sfakianos, J. P. (2025). Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU International. https://doi.org/10.1111/bju.16556
Vancouver
Ben-David R, Lidagoster S, Geduldig J, Kolanukuduru KP, Elkun Y, Tillu N, et al. Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU International. 2025. doi:10.1111/bju.16556
BibTeX
@article{BenDavid2025,
author = {Ben-David, Reuben and Lidagoster, Sarah and Geduldig, Jack and Kolanukuduru, Kaushik P and Elkun, Yuval and Tillu, Neeraja and Mandel, Asher and Almoflihi, Mohammed and Kaufmann, Basil and Attalla, Kyrollis and Mehrazin, Reza and Wiklund, Peter and Sfakianos, John P},
title = {Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16556}
}
EUVIMED